Exploring Drug Efficacy in ER-Positive Metastatic Breast Cancer

The chapter delves into the efficacy and toxicity profiles of various drugs like chamazestrant and Imluneestrant in treating ER-positive metastatic breast cancer. It discusses ongoing phase 2 and 3 studies evaluating PFS outcomes, biomarker changes, and different treatment combinations. The conversation also touches on the molecular biology and genomics associated with newer drugs like LASER-Foxifen and hints at forthcoming phase 3 data on the effectiveness of Tamoxifen in the metastatic setting.